DxRxHx
Clinical Condition Guide

Generalized
Anxiety Disorder

An anxiety disorder characterized by excessive, persistent worry about multiple domains of life, accompanied by physical tension and difficulty controlling the worry.

5-6%
Prevalence
~31
Onset Age
2:1
Ratio
50-60%
Response Rate

DSM-5-TR Diagnostic Criteria

Criterion A: Excessive Worry

Persistent worry for at least 6 months

  • • Excessive anxiety and worry occurring more days than not about a number of events or activities

Criterion B: Control

Difficulty controlling worry

  • • The individual finds it difficult to control the worry

Criterion C: Associated Symptoms

3+ required (only 1 in children):

  • • Restlessness or Feeling Keyed Up (Feeling on edge, unable to relax)
  • • Easily Fatigued (Mental and physical exhaustion from worry)
  • • Difficulty Concentrating (Mind going blank, distracted by worry)
  • • Irritability (Increased impatience and frustration)
  • • Muscle Tension (Chronic tightness, especially jaw, neck, shoulders)
  • • Sleep Disturbance (Difficulty falling/staying asleep, restless sleep)

Additional Requirements

Diagnostic caveats:

  • • Causes clinically significant distress or functional impairment
  • • Not attributable to substance use or medical condition
  • • Not better explained by another mental disorder

Assessment Protocols

Validated tools for screening and severity tracking

GAD-7

Generalized Anxiety Disorder-7

Brief 7-item self-report measure of GAD symptom severity; most widely used screening tool in primary care.

Scoring:

0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe anxiety; score ≥10 suggests GAD

Time:2-3 minutes

PSWQ

Penn State Worry Questionnaire

Criterion-standard 16-item measure of trait worry, the cardinal feature of GAD.

Scoring:

Score range 16-80; cutoff ≥62 suggests clinically significant worry; highly sensitive to treatment change

Time:5-7 minutes

HAM-A

Hamilton Anxiety Rating Scale

Clinician-rated 14-item scale assessing psychological and somatic anxiety symptoms.

Scoring:

<17 mild, 18-24 mild-moderate, 25-30 moderate-severe, >30 severe anxiety

Time:15-20 minutes

BAI

Beck Anxiety Inventory

21-item self-report focusing on somatic symptoms of anxiety over the past week.

Scoring:

0-7 minimal, 8-15 mild, 16-25 moderate, 26-63 severe anxiety

Time:5-10 minutes

Causes & Etiology

Neurobiological

  • Amygdala hyperactivity (threat detection)
  • Prefrontal cortex hypoactivity (worry regulation)
  • Anterior cingulate cortex dysfunction
  • GABA and serotonin dysregulation

Genetic

  • Heritability: 30-40%
  • Polygenic risk involving multiple genes
  • SLC6A4 polymorphisms
  • COMT gene variants

Environmental

  • Childhood adversity and overprotective parenting
  • Chronic stress and major life transitions
  • Socioeconomic instability
  • Medical illness

Psychological

  • Intolerance of uncertainty
  • Negative beliefs about worry
  • Thought-action fusion
  • Attentional bias toward threat
Evidence-Based

Scientific Sources

GAD-7 Validation

Spitzer RL, Kroenke K, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.

DSM-5-TR Criteria

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.

CBT for GAD Meta-Analysis

Cuijpers P, Cristea IA, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis. World Psychiatry. 2016;15(3):245-258.

Pharmacotherapy Efficacy

Baldwin DS, Anderson IM, et al. Evidence-based pharmacological treatment of anxiety disorders. J Psychopharmacol. 2014;28(5):403-439.

Intolerance of Uncertainty Model

Dugas MJ, Gagnon F, et al. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav Res Ther. 1998;36(2):215-226.

Neurobiology of GAD

Etkin A, Prater KE, et al. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009;66(12):1361-1372.